CAR T-cell patients are at high risk of infection due to cytokine-mediated cytopenias, myelosuppression related to chemotherapy, and CRS treatment with high-dose corticosteroids and/or IL-6 inhibitors, such as tocilizumab [8]. This evidence concerns the gene IL6 and congenital rubella syndrome.